Exclusive Webinar :Don't miss the latest webinar on Global Investing with Passive Products on June 22, 11am

Buy Ajanta Pharmaceuticals; target of Rs 1960: ICICI Direct

ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated November 04, 2020.

November 07, 2020 / 12:54 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Ajanta Pharmaceuticals

Q2 results were a beat on all fronts. Net revenues grew 7.8% YoY to Rs 702 crore, mainly due to 11.6% growth in export formulations to Rs 500 crore. Domestic growth stayed flattish at Rs 202 crore amid slow recovery in dermatology and ophthalmology segments. EBITDA margins were at 38.3% vs. 27.6% in Q2FY20. Sharp improvement in margins was led by 420 bps YoY improvement in gross margins to 78.3% and lower travel & promotional spends amid Covid. Hence, EBITDA grew 54.4% YoY to Rs 274.3 crore. PAT grew 45% YoY to Rs 170.2 crore. Delta vis-à-vis EBITDA was mainly due to higher tax rate (31.7% vs. 28.0% in Q2FY20) and lower other income.


The company remains a play on global branded generics space. We arrive at our target price of Rs 1960 based on 22x FY23E EPS of ~Rs 89.0.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Nov 7, 2020 12:54 pm

stay updated

Get Daily News on your Browser